Home > Healthcare > Medical Devices > Diagnostic Devices > Colorectal Cancer Diagnostics Market

Colorectal Cancer Diagnostics Market Share

Report ID: GMI6924
Published Date: Oct 2023
Report Format: PDF

Download Free Sample

Colorectal Cancer Diagnostics Market Share

The colorectal cancer diagnostics industry is consolidated in nature. The companies operating in this industry such as Qiagen N.V. are focusing their efforts on continuous product innovation in order to acquire substantial market share. For instance, in September 2022, Qiagen announced a strategic partnership with Neuron23, a biotechnology company to develop NGS based tests in companion diagnostic. The collaboration helped the company to enhance their R&D activities and build a strong brand image thereby enhancing overall business revenue.

Some of the eminent market participants operating in in the colorectal cancer diagnostics industry include:

Abbott Laboratories
BioMerieux SA
Becton
Dickinson and Company
GE Healthcare
Qiagen N.V
F-Hoffmann-La Roche Ltd
Siemens Healthineers
Sysmex Corporation
Thermo Fischer Scientific
Hologic Inc
Epigenomics AG

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global colorectal cancer diagnostics industry value was USD 13 billion in 2022 and is estimated to account for USD 30.2 billion by 2032.

The hospitals segment garnered USD 5,335.9 million in the year 2022 and is expected to witness substantial growth through 2032 as awareness campaigns and educational efforts conducted at hospitals have significantly influenced public understanding of cancer screenings importance.

U.S. colorectal cancer diagnostics market accounted for USD 4.3 billion revenue size in 2022 and is predicted to witness substantial market growth through 2032 attributable to factors such as the presence of major business players, an increase in colorectal cancer screening procedures, etc.

Abbott Laboratories, BioMerieux SA, Becton, Dickinson, and Company, GE Healthcare, Qiagen N.V, F-Hoffmann-La Roche Ltd, Siemens Healthineers, Sysmex Corporation, Thermo Fischer Scientific, Hologic Inc., and Epigenomics AG.